Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Key Highlights
- ➤$388.9 million cash, cash equivalents and investments; runway projected into 2029
- ➤$50.4 million third-quarter net loss, or $0.15 per share
- ➤ALPHA3 enrollment continues; next clinical update expected mid-2027
- ➤ALPHA3 enrollment expected to complete by year-end 2027
- ➤2026 operating expense guidance approximately $165 million
Expert Statements
Zachary Roberts, President and Chief Executive Officer of Allogene Therapeutics
“CAR T has transformed what's possible in medicine, but toxicity and treatment complexity have kept its full potential out of reach for too many patients”
Zachary Roberts, President and Chief Executive Officer of Allogene Therapeutics
“We believe 2027 will be an important year for cema-cel and the field, with upcoming ALPHA3 data expected to provide important insights into the potential for CAR T to be integrated into existing practice patterns, earlier in the course of a patient's disease and closer to where they receive care.”
Zachary Roberts, President and Chief Executive Officer of Allogene Therapeutics
“At the same time, our ALLO-329 data set to be released next week will begin to address an equally important question in autoimmune disease: whether we can deliver meaningful clinical benefit with less reliance on chemotherapy-based conditioning.”
Zachary Roberts, President and Chief Executive Officer of Allogene Therapeutics
“Both programs reflect our conviction that the future of CAR T will be shaped not only by what these therapies can do, but by how we make them more accessible and practical for patients.”
* Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): * ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-Pacific * Next ALPHA3 Clinical Update Anticipated in Mid-2027, with Trial Enrollment Completion Expected by Year-End 2027 * Appointed Cell Therapy Commercialization Veteran Rocio Manghani, MPH, as Vice President, Market Access, Evidence & Strategy * Investor Event at ASH to Focus on Cema-cel’s Potential to Overcome Barriers to Autologous CAR T Adoption
* Phase 1 RESOLUTION Trial in Autoimmune Disease: * Presentation at ACR Convergence (November 9) to Expand on Published Nine-Patient Abstract with Additional Patients, Longer Follow-Up Across Three ALLO-329 Dose Levels and Three Lymphodepletion Approaches * Updated Results to Highlight ALLO-329's Emerging Safety and Clinical Activity, Including a Focused Assessment of Treatment Responses in Systemic Sclerosis (Scleroderma) and New Insights into the Role of Lymphodepletion
Get started
Create a free account to read the full story.